AI赋能生物医药，天河今年首场产业对接会传递了哪些信号？

Core Insights - The event held in Tianhe District, Guangzhou, on January 6, 2026, focuses on the integration of artificial intelligence (AI) in various industries, particularly in biomedicine and new materials, aiming to foster regional industrial collaboration and ecosystem development [1][2] Group 1: AI and Industry Development - The Tianhe District has positioned AI as a key driver of industrial development, aligning with the national strategy of "AI+" as one of the eight strategic emerging industries [1][3] - The district has established a solid foundation with three trillion-level industrial clusters: finance, new-generation information technology, and high-end professional services, providing ample opportunities for AI integration [1][3] Group 2: AI in Biomedicine - The partnership between Guangdong Innovation Investment Development Co., Ltd. and global AI pharmaceutical leader JingTai Technology aims to create a platform for AI-driven drug discovery, potentially reducing the time to market for new drugs by 4 to 5 years and increasing intellectual property value by 70%-80% [2][3] - JingTai Technology has developed a new research paradigm involving AI in experimental design, robotic execution, and data feedback, gaining recognition from major global pharmaceutical companies [2] Group 3: Ecosystem Development - Tianhe District is transitioning from project implementation to ecosystem construction, emphasizing the integration of policy, technology, and capital to support high-quality economic development [4][5] - The establishment of a market-oriented operation platform aims to enhance industrial cultivation, investment attraction, and achievement transformation, thereby better serving technological innovation [5] Group 4: Financial Support and Cross-Border Cooperation - Customized financial products for AI and biomedicine companies are being offered, including long-term acquisition loans with financing ratios up to 70%, supporting enterprises in their technological innovation and industrial layout [5] - Cross-border cooperation with Hong Kong is highlighted as a potential growth area, leveraging Hong Kong's advantages in drug approval and biotech financing to enhance the biomedicine ecosystem in the Greater Bay Area [5]